ESGU, PRU, GILD, PEG: ETF Outflow Alert
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 06 2024
0mins
Should l Buy GILD?
Source: NASDAQ.COM
ESGU Share Performance: ESGU's share price has reached a 52-week high of $134.27, with a low of $100.53, indicating strong performance in the market.
ETFs Trading Dynamics: Exchange traded funds (ETFs) operate like stocks but involve trading "units" that can be created or destroyed based on investor demand, affecting the underlying holdings significantly.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GILD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GILD
Wall Street analysts forecast GILD stock price to fall
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 140.450
Low
105.00
Averages
137.88
High
154.00
Current: 140.450
Low
105.00
Averages
137.88
High
154.00
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It has a cancer program, namely TREX1. It operates in more than 35 countries worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gilead Expands Access to HIV Prevention Drug Lenacapavir
- Expanded Coverage: Gilead announced a partnership with the U.S. State Department, PEPFAR, and The Global Fund to increase access to lenacapavir for an additional 1 million people over the next three years, raising the total commitment to 3 million, significantly enhancing HIV prevention in high-incidence areas.
- Global Strategic Collaboration: By collaborating with PEPFAR and The Global Fund, Gilead leverages their expertise in country delivery and distribution to ensure lenacapavir reaches the communities in greatest need swiftly, thereby accelerating global access to HIV prevention medications.
- Long-Acting Drug Rollout: As the first HIV prevention therapy approved in the U.S., lenacapavir is expected to see a large-scale generic rollout starting in 2027, which will further reduce drug costs and expand market coverage, aiding the global fight against the HIV epidemic.
- Commitment to Innovation: Gilead's ongoing innovation in the HIV field has led to the development of 13 HIV medications, and plans to accelerate generic production through voluntary licensing agreements with six generic manufacturers to meet the growing global demand for HIV prevention.
See More
Jim Cramer's Insights on Stocks
- Gilead Sciences Outlook: Cramer expresses a positive view on Gilead Sciences, praising CEO Daniel O'Day's leadership and suggesting that the company has solid business fundamentals, recommending investors hold the stock for potential gains.
- AST SpaceMobile Potential: Cramer shows optimism for AST SpaceMobile, highlighting its unique market positioning that could present investment opportunities; while he does not explicitly call for a takeover, he draws parallels to Global Star and Amazon, hinting at possible upside.
- Nokia Growth Expectations: Cramer advises investors to hold onto Nokia shares, believing the company has another 30% upside potential, reflecting confidence in its future performance.
- Investor Education Resources: Cramer encourages investors to download his investment guide and join the CNBC Investing Club to better understand market dynamics and investment strategies, aiding them in achieving long-term wealth growth.
See More
Gilead Sciences and Nokia Stock Outlook Analysis
- Gilead Sciences Outlook: Analysts express admiration for Gilead Sciences' CEO Daniel O'Day, suggesting that the company has solid business fundamentals, recommending investors to hold the stock, which reflects confidence in its future growth.
- AST SpaceMobile Potential: Analysts highly recognize AST SpaceMobile's unique assets, and while not explicitly calling for a takeover, comparisons to Global Star and Amazon imply that the company may possess attractive potential for investors.
- Nokia Growth Potential: Analysts recommend investors to hold Nokia stock, believing there is still a 30% growth potential ahead, indicating an optimistic outlook on the company's market performance.
- Market Investment Strategy: The positive comments from analysts suggest that despite market volatility, stocks like Gilead Sciences and Nokia are still viewed as attractive investment options, potentially drawing the attention of long-term investors.
See More
Morgan Stanley Raises Gilead Price Target to $175, Maintains Overweight Rating
- Price Target Increase: Morgan Stanley raised Gilead's (GILD) price target from $171 to $175, reflecting an optimistic outlook on the company's future performance, which is expected to boost investor confidence and potentially drive the stock price higher.
- Rating Maintained: The firm continues to assign an Overweight rating to Gilead, indicating analysts' recognition of its long-term growth potential, which may attract more institutional investors to the stock.
- Model Adjustments: Morgan Stanley adjusted its models across its biopharma coverage to reflect IQVIA trends and intra-quarter updates, demonstrating keen insights into industry dynamics that will aid in more accurately forecasting the company's performance.
- Market Reaction Anticipation: With the first-quarter earnings report approaching, the heightened market focus on Gilead, combined with the analysts' positive rating and price target increase, is likely to stimulate stock price appreciation ahead of the earnings release, enhancing market confidence in its future performance.
See More
European Pharma Industry Faces Competitive Pressures
- Increased Market Competition: The European pharmaceutical industry is facing significant competitive pressures due to President Trump's drug pricing policies and the rise of China's biotech sector, leading to a shift in investments and impacting new drug launches.
- R&D Investment Shift: In 1990, Europe accounted for nearly half of global R&D, but this has plummeted to 26% today, while the U.S. share has risen to 55%, indicating a decline in Europe's position in global pharmaceutical innovation.
- Significant Policy Impact: The U.S. has imposed tariffs of up to 100% on branded drugs, which, while limited in immediate impact on companies without pricing agreements, adds to the competitive pressure on Europe's pharmaceutical sector, necessitating improvements in market conditions.
- Industry Calls for Reform: The European pharmaceutical industry urgently needs to increase investment in new medicines and improve the regulatory environment to avoid losing market share, with the EFPIA warning that without action, Europe could face a larger trade deficit.
See More
MGNX Positioned for Growth in Antibody-Drug Conjugate Market
- FDA Lifts Clinical Hold: MGNX announced that the U.S. FDA has lifted the partial clinical hold on its Phase 2 trial of Lorigerlimab, allowing the study to resume enrolling patients with advanced ovarian and gynecologic cancers, which is expected to accelerate clinical progress and patient recruitment.
- Significant Stock Surge: Following a bullish analyst call, MGNX shares surged approximately 10% on Friday, reaching their highest levels since November 2024, indicating strong market confidence in the company's growth potential, with a year-to-date increase of around 133%.
- Analyst Upgrade: B. Riley upgraded MGNX from ‘Neutral’ to ‘Buy’ with a price target of $9, driven by optimistic projections for the Antibody-Drug Conjugate (ADC) market, asserting that MGNX is uniquely positioned in the emerging “ADAM9 TOPO1i ADC” space.
- Shift in Market Sentiment: Retail sentiment for MGNX on Stocktwits shifted from ‘bearish’ to ‘bullish’, with users expressing increased optimism about the stock's valuation, reflecting a growing confidence among investors regarding the company's future prospects.
See More
Gilead Expands Access to HIV Prevention Drug Lenacapavir
- Expanded Coverage: Gilead announced a partnership with the U.S. State Department, PEPFAR, and The Global Fund to increase access to lenacapavir for an additional 1 million people over the next three years, raising the total commitment to 3 million, significantly enhancing HIV prevention in high-incidence areas.
- Global Strategic Collaboration: By collaborating with PEPFAR and The Global Fund, Gilead leverages their expertise in country delivery and distribution to ensure lenacapavir reaches the communities in greatest need swiftly, thereby accelerating global access to HIV prevention medications.
- Long-Acting Drug Rollout: As the first HIV prevention therapy approved in the U.S., lenacapavir is expected to see a large-scale generic rollout starting in 2027, which will further reduce drug costs and expand market coverage, aiding the global fight against the HIV epidemic.
- Commitment to Innovation: Gilead's ongoing innovation in the HIV field has led to the development of 13 HIV medications, and plans to accelerate generic production through voluntary licensing agreements with six generic manufacturers to meet the growing global demand for HIV prevention.
See More
Jim Cramer's Insights on Stocks
- Gilead Sciences Outlook: Cramer expresses a positive view on Gilead Sciences, praising CEO Daniel O'Day's leadership and suggesting that the company has solid business fundamentals, recommending investors hold the stock for potential gains.
- AST SpaceMobile Potential: Cramer shows optimism for AST SpaceMobile, highlighting its unique market positioning that could present investment opportunities; while he does not explicitly call for a takeover, he draws parallels to Global Star and Amazon, hinting at possible upside.
- Nokia Growth Expectations: Cramer advises investors to hold onto Nokia shares, believing the company has another 30% upside potential, reflecting confidence in its future performance.
- Investor Education Resources: Cramer encourages investors to download his investment guide and join the CNBC Investing Club to better understand market dynamics and investment strategies, aiding them in achieving long-term wealth growth.
See More
Gilead Sciences and Nokia Stock Outlook Analysis
- Gilead Sciences Outlook: Analysts express admiration for Gilead Sciences' CEO Daniel O'Day, suggesting that the company has solid business fundamentals, recommending investors to hold the stock, which reflects confidence in its future growth.
- AST SpaceMobile Potential: Analysts highly recognize AST SpaceMobile's unique assets, and while not explicitly calling for a takeover, comparisons to Global Star and Amazon imply that the company may possess attractive potential for investors.
- Nokia Growth Potential: Analysts recommend investors to hold Nokia stock, believing there is still a 30% growth potential ahead, indicating an optimistic outlook on the company's market performance.
- Market Investment Strategy: The positive comments from analysts suggest that despite market volatility, stocks like Gilead Sciences and Nokia are still viewed as attractive investment options, potentially drawing the attention of long-term investors.
See More
Morgan Stanley Raises Gilead Price Target to $175, Maintains Overweight Rating
- Price Target Increase: Morgan Stanley raised Gilead's (GILD) price target from $171 to $175, reflecting an optimistic outlook on the company's future performance, which is expected to boost investor confidence and potentially drive the stock price higher.
- Rating Maintained: The firm continues to assign an Overweight rating to Gilead, indicating analysts' recognition of its long-term growth potential, which may attract more institutional investors to the stock.
- Model Adjustments: Morgan Stanley adjusted its models across its biopharma coverage to reflect IQVIA trends and intra-quarter updates, demonstrating keen insights into industry dynamics that will aid in more accurately forecasting the company's performance.
- Market Reaction Anticipation: With the first-quarter earnings report approaching, the heightened market focus on Gilead, combined with the analysts' positive rating and price target increase, is likely to stimulate stock price appreciation ahead of the earnings release, enhancing market confidence in its future performance.
See More
European Pharma Industry Faces Competitive Pressures
- Increased Market Competition: The European pharmaceutical industry is facing significant competitive pressures due to President Trump's drug pricing policies and the rise of China's biotech sector, leading to a shift in investments and impacting new drug launches.
- R&D Investment Shift: In 1990, Europe accounted for nearly half of global R&D, but this has plummeted to 26% today, while the U.S. share has risen to 55%, indicating a decline in Europe's position in global pharmaceutical innovation.
- Significant Policy Impact: The U.S. has imposed tariffs of up to 100% on branded drugs, which, while limited in immediate impact on companies without pricing agreements, adds to the competitive pressure on Europe's pharmaceutical sector, necessitating improvements in market conditions.
- Industry Calls for Reform: The European pharmaceutical industry urgently needs to increase investment in new medicines and improve the regulatory environment to avoid losing market share, with the EFPIA warning that without action, Europe could face a larger trade deficit.
See More
MGNX Positioned for Growth in Antibody-Drug Conjugate Market
- FDA Lifts Clinical Hold: MGNX announced that the U.S. FDA has lifted the partial clinical hold on its Phase 2 trial of Lorigerlimab, allowing the study to resume enrolling patients with advanced ovarian and gynecologic cancers, which is expected to accelerate clinical progress and patient recruitment.
- Significant Stock Surge: Following a bullish analyst call, MGNX shares surged approximately 10% on Friday, reaching their highest levels since November 2024, indicating strong market confidence in the company's growth potential, with a year-to-date increase of around 133%.
- Analyst Upgrade: B. Riley upgraded MGNX from ‘Neutral’ to ‘Buy’ with a price target of $9, driven by optimistic projections for the Antibody-Drug Conjugate (ADC) market, asserting that MGNX is uniquely positioned in the emerging “ADAM9 TOPO1i ADC” space.
- Shift in Market Sentiment: Retail sentiment for MGNX on Stocktwits shifted from ‘bearish’ to ‘bullish’, with users expressing increased optimism about the stock's valuation, reflecting a growing confidence among investors regarding the company's future prospects.
See More
